Bosaya Aukelso FDA launch

October 2, 2025
Amgen Prolia Xgeva biosimilars
Biocon Biologics Amgen settlement
Biocon Biologics patent litigation settlement
Biocon BSE stock update
Biocon October 2025 launch news
Biocon share price news
Biocon US biosimilars launch
Bosaya Aukelso FDA launch
BUSINESS
Rajasthan
Udaipur

Biocon Gains Over 1% as Subsidiary Signs Settlement and License Deal with Amgen | Udaipur Kiran

Mumbai (Udaipur Kiran News): Shares of Biocon Ltd rose over 1.6% in Wednesday’s trading session after its subsidiary, Biocon Biologics, signed a settlement and license agreement with Amgen Inc. paving the way for the commercial launch of its biosimilar drugs Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States. The stock was trading at ₹346.35, […]